Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

被引：22
|
作者：
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Urban, Laszlo
Caro, Reyes Bernabe
Park, Keunchil
Sakai, Hiroshi
Ohe, Yuichiro
Nishio, Makoto
Pluzanski, Adam
Ramalingam, Suresh S.
Brahmer, Julie R.
Borghaei, Hossein
O'Byrne, Kenneth John
Hellmann, Matthew D.
Memaj, Arteid
Bushong, Judith
Tran, Phuong
Reck, Martin
机构：
[1] Univ Complutense, CNIO H12o Lung Canc Clin Res Unit, Hosp Univ 12 Octubre, Madrid, Spain
[2] CiberOnc, Madrid, Spain
[3] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[4] UMF Iuliu Hatieganu, Cluj Napoca, Romania
[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[6] Matrai Gyogyint, Matrahaza, Hungary
[7] Hosp Univ Virgen Del Rocio, Inst Biomed Seville, Seville, Spain
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Canc Ctr, Saitama, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[15] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[16] Princess Alexandra Hosp, Brisbane, Qld, Australia
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Bristol Myers Squibb, Springfield, PA USA
[20] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
    Lei, Ming
    Doki, Yuichiro
    Kitagawa, Yuko
    Kato, Ken
    Chau, Ian
    Yao, Jin
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Blum Murphy, Mariela A.
    Novosiadly, Ruslan
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
  • [42] Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227
    Peters, S.
    Penrod, J.
    Li, J.
    Lubinga, S.
    Gupta, R.
    Bushong, J.
    Rizzo, J.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S32 - S33
  • [43] Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Reck, M.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. S.
    Caro, R. Bernabe
    Linardou, H.
    Burgers, J.
    Gallardo, C.
    Nishio, M.
    Peters, S.
    Paz-Ares, L. G.
    Hellmann, M. D.
    Borghaei, H.
    Ramalingam, S. S.
    O'Byrne, K.
    Hu, N.
    Bushong, J.
    Eccles, L.
    Grootendorst, D.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1430 - S1431
  • [44] First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
    Reck, M.
    Ciuleanu, T-E.
    Cobo, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E.
    Bennouna, J.
    Cheng, Y.
    Paz-Ares, L.
    Lu, S.
    John, T.
    Padilla, B.
    Sun, X.
    Moisei, A.
    Yan, J.
    Yuan, Y.
    Blum, S. I.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1187 - S1188
  • [45] First-line Therapy with Nivolumab (NIVO) plus Ipilimumab (IPI)+2 Cycles of Chemotherapy (chemo) vs Chemotherapy alone (4 Cycles) in Patients (pts) with metastatic non-small cell Lung Cancer (mNSCLC): 3-year Update of CheckMate 9LA
    Misch, D.
    Paz-Ares, L. G.
    Ciuleanu, T. -E
    Cobo-Dols, M.
    Bennouna, J.
    Cheng, Y.
    Mizutani, H.
    Lingua, A.
    Reyes, F.
    Reinmuth, N.
    Menezes, J.
    Jassem, J.
    Protsenko, S.
    Feeney, K.
    Jimenez, de la Mora E.
    Lu, S.
    John, T.
    Carbone, D. P.
    Zhang, X.
    Hu, N.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 55 - 56
  • [46] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
    Kato, Ken
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Patel, Apurva
    Hu, Nan
    Matsumura, Yasuhiro
    Chau, Ian
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
  • [47] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [48] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
    Chau, I.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M.
    Holtved, E.
    Murphy, M. Blum
    Abdullaev, S.
    Soleymani, S.
    Lei, M.
    Kato, K.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
  • [49] CheckMate 227: Nivolumab plus Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden
    Mathias, C.
    Reck, M.
    Hellmann, M.
    Ramalingam, S.
    Brahmer, J.
    O'Byrne, K.
    Bhagavatheeswaran, P.
    Nathan, F.
    Borghaei, H.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S153
  • [50] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Palaia, Jennell
    Horton, Viviana Garcia
    Zhou, Zheng-Yi
    Christensen, Dana
    Rosenblatt, Lisa
    McDonald, Laura
    Ratto, Barbara
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345